March 24th, 2011
Oh That? Deceptive Marketing Settlement Doesn't Stop Seroquel Advertising
Google the word “depression” and the first search result you’ll get is for the antipsychotic Seroquel XR.
Visit WebMD and the home page hosts similar ads for Seroquel XR, above and adjacent to the lead news story.
Who would know AstraZeneca inked the largest multi-state consumer protection settlement on record relating to deceptive Seroquel marketing just this week? For $68.5 million? Only a year after inking a similar settlement related to burying side effect and safety information for $520 million with the government?
Who would know AstraZeneca has already settled nearly 25,000 personal injury lawsuits pertaining to Seroquel with more to come, says ABC news?
First approved in 1997, Seroquel has enjoyed the camel-nose-under-the-tent phenomenon known as indications creep. First approved for schizophrenia, it was later approved for bipolar disorder and psychiatric conditions in children. But it was Seroquel’s 2009 approval as an add-drug for depression that helped it reach its spectacular sales of $5.3 billion in 2010 thanks to the U.S.’ walloping depression “market” of 20 million.
Seroquel’s blood sugar, weight gain and heart side effects are well known. That’s why FDA regulators opposed its use as a first choice, stand-alone treatment for the 10 percent of the U.S. population with depression when safer drugs exist. “I saw no clear advantage demonstrated in efficacy,” said Dr. Wayne Goodman who chaired the FDA panel considering the depression indication. “There were side effects, and I would expect unintended consequences associated with wide-scale use of the drug.”
The drug also can cause increased mortality in elderly patients with dementia-related psychosis, suicidality, neuroleptic malignant syndrome, cataracts, seizures, increases in blood pressure and movement disorders in neonates when their mothers take it.
Seroquel’s fraud trail is also well known with more than six conflict of interest scandals swirling around Seroquel researchers and promoters. Psychiatrist Richard Borison was sentenced to a 15-year prison sentence in 1998 for a pay-to-play Seroquel research scheme which helped establish Seroquel’s original perception as safe.